<DOC>
	<DOCNO>NCT01173848</DOCNO>
	<brief_summary>The purpose study examine effectiveness vitamin D3 versus vitamin D2 raise vitamin D level suppress parathyroid hormone level patient kidney disease dialysis .</brief_summary>
	<brief_title>Vitamin D Supplement Study Stage Three Four Chronic Kidney Disease ( CKD ) Patients</brief_title>
	<detailed_description>Subjects randomize assigned one treatment group ( D2 D3 ) . Subjects dispense supply 1.25 mg cholecalciferol/ergocalciferol tablet , depend randomization outcome . The number pill dispensed medication instruction determine 25OHD level K/DOQI guideline . Both Study personnel subject blind randomization group . The treatment phase 24 week duration lab visit every 6 week . All laboratory specimens draw either CCF Main hospital lab CCF family Health center lab . Subjects telephone interview week 4 , 10 , 16 , 22 possibly week 28 34 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Adults â‰¥ 18 year Chronic kidney disease stage 34 ( eGFR 1559 mL/min/1.73m2 body surface area , calculate use MDRD Study equation GFR calculator ) Hypovitaminosis D ( serum 25OHD &lt; 31 ng/mL ) Secondary hyperparathyroidism ( Intact PTH &gt; 70 pg/mL stage 3 , iPTH &gt; 110 pg/mL stage 4 ) Initiation vitamin D therapy time lab draw use screen screen process History liver failure History intestinal malabsorption chronic diarrhea Serum calcium level great 10.2 mg/dL Treatment activate vitamin D formulation ( calcitriol , doxercalciferol paricalcitol ) within past 6 month Treatment phenobarbital , phenytoin , rifampicin , sucralfate , steroid , digoxin , medication could affect vitamin D metabolism Primary hyperparathyroidism , active prior history Active malignancy exclude basal cell localize squamous cell skin cancer Subject pregnant ( e.g . positive HCG test ) breastfeeding Refusal use highly effective contraceptive measure ( determine investigator ) throughout treatment phase study Serum phosphorus level great 4.5 treatment oral phosphate binder within past 6 month Treatment cinacalcet calcimimetic within past 6 month Anticipated dialysis within 6 month randomization Inability swallow tablet Known sensitivity , intolerance , adverse response study drug would prevent compliance study medication Have unstable medical condition , define hospitalize within 30 day screen , expectation recurrent hospital admission life expectancy le 6 month judgment investigator Subject currently enrol , few 30 day pass since subject complete another investigational device drug study ( ) ; subject receive another investigational agent ( ) . Current treatment vitamin D 50,000 IU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>CKD</keyword>
	<keyword>Vitamin D</keyword>
</DOC>